866-997-4948(US-Canada Toll Free)

Ramucirumab Analysis and Market Forecasts from 2014 to 2020

Published By :

GlobalData

Published Date : Jul 2011

Category :

Therapeutic Area

No. of Pages : 28 Pages


GlobalDatas pharmaceuticals report, Ramucirumab Analysis and Market Forecasts from 2014 to 2020 provides Ramucirumab sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2014-2020). The report also includes information on Liver Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope
  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Ramucirumab including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Ramucirumab including efficacy, safety, pricing and other details which influence influence its sales potential
  • Detailed sales forecast for 2014-2020 for Ramucirumab in each of the seven major markets
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Content

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Introduction 4
2.1 Liver Cancer Market 4
2.2 Epidemiology 4
2.3 Etiology 5
2.3.1 Hepatitis B Infection 5
2.3.2 Hepatitis C Infection 5
2.3.3 Alcohol 5
2.3.4 Aflatoxin B1 6
2.3.5 Hemochromatosis 6
2.3.6 Diabetes and Obesity 6
2.3.7 Cirrhosis 6
2.4 GlobalData Report Guidance 6

3 Liver Cancer : Market Characterization 7
3.1 Liver Cancer Market 7
3.2 Liver Cancer Market Forecasts and CAGR 7
3.3 Drivers for the Liver Cancer Market 7
3.3.1 High Incidence 8
3.3.2 High Mortality 8
3.3.3 Large Unmet Need 9

4 TumorNodeMetastases (TNM) Classification of Liver Cancer 10

5 Ramucirumab 11
5.1 Introduction 11
5.2 Mechanism of Action 11
5.3 Clinical Studies 11
5.3.1 Phase III Study of Ramucirumab (IMC1121B) and BSC (Best Supportive Care) Versus Placebo and BSC as Secondline Treatment in Patients with Liver Cancer after Firstline Therapy with Sorafenib (REACH) 11
5.3.2 Phase II Study of Ramucirumab (IMC1121B) in Patients with Liver Cancer Who have not Previously been Treated with Chemotherapy 11
5.4 Approval Status of Ramucirumab 12
5.5 Factors Affecting Sales of Ramucirumab 12
5.5.1 Liver Cancer Market 12
5.5.2 Beneficial for Nexavar (sorafenib) failed Patients as Secondline Treatment 12
5.5.3 Comparison with Competitors 12
5.6 Drug Risk Benefit Score 12
5.7 Intensity of Competition 12
5.8 Sales Forecasts 13
5.8.1 Target Patient Pool of Ramucirumab 13
5.8.2 Dosing 13
5.8.3 Market Penetration 13
5.8.4 Annual Cost of Therapy 14
5.8.5 Sales Projections of Ramucirumab 15

6 Liver Cancer Market: Appendix 24
6.1 Market Definitions 24
6.2 List of Abberiviations 24
6.3 Research Methodology 24
6.3.1 Coverage 24
6.3.2 Secondary Research 24
6.3.3 Forecasting 25
6.3.4 Number of Patients Approved to take the Drug 25
6.3.5 Net Penetration of Drug 26
6.3.6 Net Annual Dosing 27
6.3.7 Annual Cost of Therapy 27
6.3.8 Primary Research 27
6.3.9 Expert Panels 27
6.4 Drug Sales Estimates Model 27
6.5 Contact Us 27
6.6 Disclaimer 28
6.7 Sources 28

List of Table


Table 1: Liver Cancer, Incidences and Mortality, 20082030 4
Table 2: Clinical Trial Results 11
Table 3: Approval Status of Ramucirumab 12
Table 4: Annual Cost of Therapy 14
Table 5: Ramucirumab, Liver Cancer, Global, Sales Forecasts ($m), 20142020 15
Table 6: Ramucirumab, Liver Cancer, The US, Sales Forecasts ($m), 20142020 16
Table 7: Ramucirumab, Liver Cancer, The UK, Sales Forecasts ($m), 20152020 17
Table 8: Ramucirumab, Liver Cancer, France, Sales Forecasts ($m), 20152020 18
Table 9: Ramucirumab, Liver Cancer, Germany, Sales Forecasts ($m), 20152020 19
Table 10: Ramucirumab, Liver Cancer, Italy, Sales Forecasts ($m), 20142020 20
Table 11: Ramucirumab, Liver Cancer, Spain, Sales Forecasts ($m), 20152020 21
Table 12: Ramucirumab, Liver Cancer, Japan, Sales Forecasts ($m), 20152020 22

List of Chart


Figure 1: Fatality = [(% Distribution of Incidence) (% Distribution of Mortality)] of Most Common Cancers 5
Figure 2: Liver Cancer, Global, Market Size Forecast ($m), 20102020 7
Figure 3: Liver Cancer, Worldwide, Incidence (in millions), 20082030 8
Figure 4: Oncology, Worldwide, Incidence (in millions), 20082030 8
Figure 5: Liver Cancer, Worldwide, Mortality (in millions), 20082030 9
Figure 6: Classification of Liver Cancer 10
Figure 7: Drug Model Diagram of Ramucirumab 13
Figure 8: Ramucirumab, Liver Cancer, Global, Sales Forecasts ($m), 20142020 15
Figure 9: Ramucirumab, Liver Cancer, The US, Sales Forecasts ($m), 20142020 16
Figure 10: Ramucirumab, Liver Cancer, The UK, Sales Forecasts ($m), 20152020 17
Figure 11: Ramucirumab, Liver Cancer, France, Sales Forecasts ($m), 20152020 18
Figure 12: Ramucirumab, Liver Cancer, Germany, Sales Forecasts ($m), 20152020 19
Figure 13: Ramucirumab, Liver Cancer, Italy, Sales Forecasts ($m), 20152020 20
Figure 14: Ramucirumab, Liver Cancer, Spain, Sales Forecasts ($m),20152020 21
Figure 15: Ramucirumab, Liver Cancer, Japan, Sales Forecasts ($m), 20152020 22
Figure 16: Ramucirumab, Liver Cancer, Global, Sales Distribution (%), 2020 23
Figure 17: Drug Model Diagram 26
Figure 18: Patients Approved for the Drug 26

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *